Covidien Introduces New Treatment for Drug-Resistant Hypertension

PARIS--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, will unveil its new OneShot™ renal denervation system at the EuroPCR congress in Paris, France, on May 16, 2012. Adding to the Company’s broad and growing vascular therapies portfolio, the OneShot system is designed to treat patients with hypertension who are not responsive to traditional medical therapy.

MORE ON THIS TOPIC